Comparative Pharmacology
Head-to-head clinical analysis: ANAPROX DS versus CHILDREN S MOTRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANAPROX DS versus CHILDREN S MOTRIN.
ANAPROX DS vs CHILDREN'S MOTRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing pain, fever, and inflammation.
550 mg orally every 8 to 12 hours; maximum 1375 mg/day.
200-400 mg orally every 6-8 hours as needed; maximum 1200 mg/day without prescription, extended release forms: 600-800 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 12–17 hours (mean ~14 hours), allowing twice-daily dosing. Steady-state is achieved after 4–5 doses.
2-4 hours in children; prolonged in neonates and hepatic impairment.
Renal elimination of naproxen and its metabolites accounts for approximately 95% of the dose, with about 60% as unchanged drug and 40% as conjugated or hydroxylated metabolites. Biliary/fecal excretion is negligible (<5%).
Renal (90%) as inactive metabolites and conjugates; fecal (<5%).
Category C
Category C
NSAID
NSAID